David Larson1, Piyush Patel2, Anne Marie Salapatek2, Peter Couroux2, Don Whitehouse3, Adela Pina4, Jacqueline L Johnson4, Michelle L Sever4, Srinath Sanda3, Julian Poyser5, Theresa Allio5, Guy W Scadding6, Tielin Qin7, Mohamed H Shamji8, William W Kwok9, Eddie A James9, Deanna French10, Alina Lelic11, Mark Larché12, Matthew C Altman13, Alkis Togias5, Stephen R Durham8. 1. The Immune Tolerance Network, Bethesda, Md. Electronic address: dlarson@immunetolerance.org. 2. Inflamax Research Limited, DBA Cliantha Research, Mississauga, Canada. 3. Immune Tolerance Network, San Francisco, Calif. 4. Rho Federal Systems Division, Durham, NC. 5. National Institute of Allergy and Infectious Diseases, Bethesda, Md. 6. MRC and Asthma UK, Centre in Allergic Mechanisms of Asthma, London, United Kingdom. 7. The Immune Tolerance Network, Bethesda, Md. 8. MRC and Asthma UK, Centre in Allergic Mechanisms of Asthma, London, United Kingdom; Immunomodulation and Tolerance Group, Allergy and Clinical Immunology, Section of Inflammation Repair and Development, National Heart and Lung Institute, Imperial College London, London, United Kingdom. 9. Benaroya Research Institute, Department of Translational Research, Seattle, Wash. 10. McMaster University, Hamilton, Ontario, Canada. 11. Human Immunology Testing Suite, McMaster University, Hamilton, Ontario, Canada. 12. McMaster University, Hamilton, Ontario, Canada; Divisions of Clinical Immunology & Allergy and Respirology, Department of Medicine, Firestone Institute of Respiratory Health, The Research Institute, St Joe's Hamilton, Hamilton, Canada. 13. Department of Medicine, University of Washington, Seattle, Wash; Benaroya Research Institute, Systems Immunology Division, Seattle, Wash.
Abstract
BACKGROUND: The direct-instillation nasal allergen challenge (NAC) and the environmental exposure chamber (EEC) are 2 methods of conducting controlled allergen provocations. The clinical and biological comparability of these methods has not been thoroughly investigated. OBJECTIVE: We sought to compare clinical and immunologic responses to cat allergen in NAC versus EEC. METHODS: Twenty-four participants were randomized to receive either NAC followed by a 2-day challenge in an EEC or a 2-day challenge in an EEC followed by NAC. Challenges were separated by 28-day washout periods. We measured total nasal symptom scores, peak nasal inspiratory flow, nasal (0-8 hours) and serum cytokines, serum antibodies, peripheral blood antigen-specific T lymphocytes, and gene expression in nasal scrapings. The primary outcome was the total nasal symptom score area under the curve for the first 3 hours after allergen exposure in NAC or after initiation of exposure in EEC. RESULTS: Both challenges increased IL-5 and IL-13 in nasal fluids and serum and resulted in altered nasal cell expression of gene modules related to mucosal biology and transcriptional regulation. Changes in gene modules, more so than cytokine measurements, showed significant associations with total nasal symptom score and peak nasal inspiratory flow. Overall, EEC exposure generated larger responses and more early terminations compared with NAC. Although the 2 challenges did not correlate in symptom magnitude or temporality, striking correlations were observed in cytokine levels. CONCLUSIONS: Although clinical outcomes of NAC and EEC were temporally different and nonequivalent in magnitude, immunologic responses were similar. Selection of a particular allergen challenge method should depend on considerations of study objectives and cost.
BACKGROUND: The direct-instillation nasal allergen challenge (NAC) and the environmental exposure chamber (EEC) are 2 methods of conducting controlled allergen provocations. The clinical and biological comparability of these methods has not been thoroughly investigated. OBJECTIVE: We sought to compare clinical and immunologic responses to cat allergen in NAC versus EEC. METHODS: Twenty-four participants were randomized to receive either NAC followed by a 2-day challenge in an EEC or a 2-day challenge in an EEC followed by NAC. Challenges were separated by 28-day washout periods. We measured total nasal symptom scores, peak nasal inspiratory flow, nasal (0-8 hours) and serum cytokines, serum antibodies, peripheral blood antigen-specific T lymphocytes, and gene expression in nasal scrapings. The primary outcome was the total nasal symptom score area under the curve for the first 3 hours after allergen exposure in NAC or after initiation of exposure in EEC. RESULTS: Both challenges increased IL-5 and IL-13 in nasal fluids and serum and resulted in altered nasal cell expression of gene modules related to mucosal biology and transcriptional regulation. Changes in gene modules, more so than cytokine measurements, showed significant associations with total nasal symptom score and peak nasal inspiratory flow. Overall, EEC exposure generated larger responses and more early terminations compared with NAC. Although the 2 challenges did not correlate in symptom magnitude or temporality, striking correlations were observed in cytokine levels. CONCLUSIONS: Although clinical outcomes of NAC and EEC were temporally different and nonequivalent in magnitude, immunologic responses were similar. Selection of a particular allergen challenge method should depend on considerations of study objectives and cost.
Authors: Guy W Scadding; Moises A Calderon; Virginia Bellido; Gitte Konsgaard Koed; Niels-Christian Nielsen; Kaare Lund; Alkis Togias; Deborah Phippard; Laurence A Turka; Trevor T Hansel; Stephen R Durham; Peter Adler Wurtzen Journal: J Immunol Methods Date: 2012-06-30 Impact factor: 2.303
Authors: Mark W Tenn; Lisa M Steacy; Daniel E Adams; Terry J Walker; Anne K Ellis Journal: Ann Allergy Asthma Immunol Date: 2019-04-06 Impact factor: 6.347
Authors: Mena Soliman; Michelle L North; Lisa M Steacy; Jenny Thiele; Daniel E Adams; Anne K Ellis Journal: Ann Allergy Asthma Immunol Date: 2014-09 Impact factor: 6.347
Authors: Amedee Renand; Mohamed H Shamji; Kristina M Harris; Tielin Qin; Erik Wambre; Guy W Scadding; Peter A Wurtzen; Stephen J Till; Alkis Togias; Gerald T Nepom; William W Kwok; Stephen R Durham Journal: J Allergy Clin Immunol Date: 2017-11-09 Impact factor: 10.793
Authors: R M Naclerio; D Proud; A G Togias; N F Adkinson; D A Meyers; A Kagey-Sobotka; M Plaut; P S Norman; L M Lichtenstein Journal: N Engl J Med Date: 1985-07-11 Impact factor: 91.245
Authors: G W Scadding; A O Eifan; M Lao-Araya; M Penagos; S Y Poon; E Steveling; R Yan; A Switzer; D Phippard; A Togias; M H Shamji; S R Durham Journal: Allergy Date: 2015-04-06 Impact factor: 13.146
Authors: Matthew C Altman; Michelle A Gill; Elizabeth Whalen; Denise C Babineau; Baomei Shao; Andrew H Liu; Brett Jepson; Rebecca S Gruchalla; George T O'Connor; Jacqueline A Pongracic; Carolyn M Kercsmar; Gurjit K Khurana Hershey; Edward M Zoratti; Christine C Johnson; Stephen J Teach; Meyer Kattan; Leonard B Bacharier; Avraham Beigelman; Steve M Sigelman; Scott Presnell; James E Gern; Peter J Gergen; Lisa M Wheatley; Alkis Togias; William W Busse; Daniel J Jackson Journal: Nat Immunol Date: 2019-04-08 Impact factor: 25.606
Authors: G W Scadding; A Eifan; M Penagos; A Dumitru; A Switzer; O McMahon; D Phippard; A Togias; S R Durham; M H Shamji Journal: Clin Exp Allergy Date: 2015-03 Impact factor: 5.018
Authors: Matthew C Altman; Agustin Calatroni; Sima Ramratnam; Daniel J Jackson; Scott Presnell; Mario G Rosasco; Peter J Gergen; Leonard B Bacharier; George T O'Connor; Megan T Sandel; Meyer Kattan; Robert A Wood; Cynthia M Visness; James E Gern Journal: J Allergy Clin Immunol Date: 2021-03-10 Impact factor: 10.793
Authors: Gail M Gauvreau; Beth E Davis; Guy Scadding; Louis-Philippe Boulet; Leif Bjermer; Adam Chaker; Donald W Cockcroft; Barbro Dahlén; Wyste Fokkens; Peter Hellings; Nikolaos Lazarinis; Paul M O'Byrne; Ellen Tufvesson; Santiago Quirce; Maurits Van Maaren; Frans H de Jongh; Zuzana Diamant Journal: Eur Respir J Date: 2022-08-25 Impact factor: 33.795
Authors: Daniel J Jackson; William W Busse; Leonard B Bacharier; Meyer Kattan; George T O'Connor; Robert A Wood; Cynthia M Visness; Stephen R Durham; David Larson; Stephane Esnault; Carole Ober; Peter J Gergen; Patrice Becker; Alkis Togias; James E Gern; Mathew C Altman Journal: J Allergy Clin Immunol Date: 2020-04-22 Impact factor: 10.793